- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Anti-neuropathic analgesics may ease pain in IBS patients, finds Study
London, UK: A systematic review by Andrew Lambarth and the team revealed that anti-neuropathic analgesics were helpful in managing pain in patients with irritable bowel syndrome (IBS). However, the researchers further add that further studies are needed for potentially considering parenteral administration and agents with minimal gastrointestinal motility effects.
The findings of the study are published in the journal Neurogastroenterology & Motility.
Irritable bowel syndrome is characterized by severe abdominal pain and cramping. Very few people with IBS have reported severe signs and symptoms. Few people control by managing diet, lifestyle, and stress. More-severe symptoms are treated with medication and counseling. Driving pain in IBS is said to be associated with neuropathic mechanisms, antineuropathic medication might be an option.
The objective of the study was to evaluate the role of anti-neuropathic medicines in the management of pain in IBS based on systematic review of available evidence.
The study was a systematic review that searched scientific repositories for trials investigating conventional oral, or parenteral, pharmaceutical antineuropathic treatments in patients with IBS. The primary outcome was related to severe to moderate pain, and selected secondary outcomes.
Study included 13 studies with 629 participants, six investigated amitriptyline, three duloxetine, three pregabalin, and one gabapentin.
The results of the study were:
• There was considerable methodological and statistical heterogeneity, hence a narrative synthesis and limited meta-analysis were performed.
• Amitriptyline was most extensively studied, only in diarrhea-predominant patients. In individual trials, amitriptyline, pregabalin, and gabapentin generally appeared beneficial for pain outcomes.
• Duloxetine studies also tended to report improvements in pain, all were un-controlled trials with a high risk of bias.
• Meta-analysis of three studies (n = 278) yielded a pooled relative-risk of 0.50 for not improving with an anti-neuropathic agent vs control. No eligible studies were found that investigated the role of parenteral anti-neuropathics.
Lambarth and the team concluded that "Anti-neuropathic analgesics may improve pain in IBS, and deserve further high-quality investigation, potentially considering parenteral administration and agents with minimal gastrointestinal motility effects. Investigation of amitriptyline's efficacy in non-diarrhea-predominant subtypes is currently lacking, and we recommend particular caution for its use in IBS-C."
Reference: DOI: 10.1111/nmo.14289
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751